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Abstract
Aims In vitro, beta cells immediately secrete stored but
readily releasable insulin in response to a rise of glucose.
During a prolonged insulin response, this is followed by
newly synthesized insulin. Our aim was to develop an
in vivo test to determine the ratio between readily available
and newly synthesized insulin after a stimulus in humans
by labelling newly synthesized insulin.
Methods A stable isotope tracer of 1.0 g 13C leucine with
C-peptide as target peptide was administered 45 min prior
to 75 g glucose load of a frequently blood sampled
210-min oral glucose tolerance test (OGTT). Our OGTT
also encompassed collection of urine, which has a high
content of C-peptide. Prior, the optimal conditions under
which the tracer 13C leucine was administered for enrich-
ment of (pre) proinsulin were established. Also, techniques
to obtain urinary C-peptide under highly purified circum-
stances were set up. Our main outcome measure was the
stable isotope enrichment of de novo C-peptide, which we
related to early plasma insulin and glucose AUC. Twelve
healthy Caucasian individuals (M4F8, age 41.8 ± 2.3,
BMI 28.3 ± 1.7) with normal glucose tolerance underwent
our OGTT.
Results We found that during a 75-g OGTT, newly syn-
thesized insulin contributed approximately 20 % of total
insulin secretion. The pattern of isotope enrichment
obtained by collecting multiple urine voids was suggestive
that the newly synthesized insulin contributes to the late
phase of insulin secretion. De novo C-peptide correlated
negatively with both early plasma insulin AUC
(r = -0.629, P = 0.028) and early plasma glucose AUC
(r = -0.605, P = 0.037).
Conclusions With stable isotope technique added to
OGTT, we were able to measure newly synthesized insulin
in healthy individuals. This new technique holds the pro-
mise that it is feasible to develop a direct in vivo beta cell
function test.
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Nonstandard abbreviations used
GLUT2 Glucose transporter 2
RRP Readily releasable pool




MPE Mole per cent excess
FSR Fractional synthesis rate
Background
Abnormal function of the pancreatic beta cells is crucial to
the development of type 2 diabetes (T2D) [1]. An in vivo
test of the dynamics of insulin excretion could be used in
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pathogenetic studies and to examine drug effects in patients
with T2D. In the present study, we explored whether it is
feasible to develop a test with a stable isotope tracer to
quantify the newly synthesized insulin.
Insulin synthesis and secretion by beta cells is regulated
predominantly by changes in plasma glucose concentra-
tions and in particular by the rate of these changes (sup-
plemental figure 1) [2, 3]. Following an acute rise of
glucose concentrations, a biphasic insulin secretion
response occurs [4–6]. This results from the glucose
transport into beta cells through the glucose transporter 2
(GLUT2) [7], which activates calcium-dependent trigger-
ing as well as calcium-independent amplifying pathways
[8]. In the so-called storage-limited model [9–13], insulin
is secreted by exocytosis of two distinct pools of granules,
which are the storage and trafficking units for insulin
within beta cells as well as the site of conversion from
predecessor (pre) proinsulin to insulin and co-secreted
C-peptide [14]. A ‘readily releasable pool’ (RRP) of
granules near the plasma membrane is responsible for the
rapid first-phase release (via the triggering pathway), and
the translocation of a more distal ‘storage granule pool’
(SGP) serves as replenishment of the RRP and results in
the more sustained second phase [15, 16]. After an in vitro
glucose stimulus, rat pancreatic islets have a biphasic
insulin response and synthesize de novo proinsulin, which
is stored in newly synthesized granules and subsequently
secreted after 1 h [17, 18]. However, the dynamics of
newly synthesized insulin and granular secretion of (de
novo) insulin have not yet been investigated in humans
in vivo.
In the present study, we determined insulin secretory
function with a novel method by following insulin kinetics
during an oral glucose tolerance test (OGTT) preceded by
administration of a bolus of the stable isotope tracer 13C
leucine. We hypothesized that the in vitro findings would
be reflected in the time course of changes in labelled and
unlabelled insulin and C-peptide, providing an in vivo test
to characterize beta cell dynamics in humans.
Methods
Study design
Firstly, we optimized our method using 13C leucine during
an OGTT according to an earlier described bolus dose
technique [19–21], by examining dosage and distribution.
The equilibrium phase between the isotope enrichment in
the extracellular fluid was assessed by measuring 13C leu-
cine in plasma and the isotope enrichment in the intracel-
lular fluid assessed by measuring the transamination
product of intracellular leucine a-ketoisocaproic acid
(KIC) in both plasma and saliva. We also assessed the
potential stimulatory effects of 13C leucine on insulin or
C-peptide, as doses with essential amino acids may affect
various metabolic processes in tissues [22, 23]. C-peptide
de novo synthesis was calculated by its fractional synthesis
rate (FSR). We tested whether 13C enrichment was derived
from purified C-peptide accurately by comparing several
procedures. After standardization of our protocol, we used
the 13C leucine OGTT among subjects with normal glucose
tolerance and compared the enrichment results with stan-
dard OGTT parameters. On top of basal enrichment of
C-peptide, an increase in this ratio during OGTT represents
de novo synthesized insulin (illustrated schematically in
Fig. 1a).
Subjects
We had two study groups of healthy volunteers, one for the
pilot phase (n = 12) in which we explored, developed and
tested the method and thereafter a group (n = 12) to per-
form the newly developed analyses. In the pilot phase, with
subgroups obtained from the 12 healthy individuals, we
tested a number of components of the method, regarding
dosage, equilibrium stage and final precursor enrichment
(KIC) curves, based on the availability of samples on a
given time point. These individuals were not on medication
known to influence glucose metabolism and did not have
endocrine, hepatic and renal disease. The WHO criteria for
fasting and 120-min plasma glucose values were used to
categorize the study subjects as being in a normal glucose
tolerance state. The 13C leucine OGTT was performed at
the clinical research unit of the department of Internal
Medicine of Erasmus MC. Informed written consent for the
study was obtained from all participants, and the Erasmus
Medical Centre Medical Ethics Review Board approved
the study protocol.
Anthropomorphic measurements
Body height and weight were measured to the nearest
0.1 cm and 0.1 kg, respectively. Waist was measured in cm
halfway between the lowest rib and the iliac crest, hip was
measured as the maximum circumference of the hips in the
standing position in cm, and from these measurements, the
waist-to-hip ratio was calculated. Systolic and diastolic
blood pressures were measured with an electronic blood
pressure monitor (Datascope Accutorr Plus Inc., Montvale,
NJ) after 5-min rest in the sitting position.
Standardized 13C leucine OGTT
The timing of sampling is shown in Fig. 1b. A total of 75 g
glucose was dissolved in 200 ml H2O and administered
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orally after a 10-h overnight fast. A bolus dose of 1 g 13C
leucine was dissolved in 150 ml H2O and administered
orally 45 min (-45 min) prior to this oral glucose load.
Venous blood samples were drawn before the oral intake of
the 13C leucine solution (-60 min) and thereafter
(-15 min). After glucose load, venous blood samples were
drawn at time points 15, 30, 45, 60, 90, 120, 150, 180 and
210 min for measurement of glucose, insulin and C-peptide
concentrations (11 sampling time points in total). Urine
voids were collected in the fasting state (before oral 13C
leucine solution intake) and during OGTT (total urine
collected in period after 13C leucine solution intake until
210 min post-glucose load). In these two collections,
C-peptide concentrations were measured. For a subset of
individuals, urine collection during OGTT was performed
in multiple portions, enabling us to observe possible trends
Fig. 1 a Model of 13C leucine tracer incorporation in precursor amino acid pool for enrichment of de novo insulin and C-peptide and
b schematic overview 13C leucine OGTT sampling
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over time. In supplementary material, we explain how
enrichment was measured in purified urinary C-peptide.
For all subjects, we performed these analyses in triplicate
from the start of solid-phase extraction.
Measurements
Insulin and C-peptide concentrations are given in pmol/l
and glucose concentrations given in mmol/l. Area under
curve (AUC) of C-peptide and glucose was calculated
according to the trapezoid method [24].
Calculations of beta cell function enrichment parameters.
Dependency on de novo insulin Enrichment expressed in
tracer/tracee ratio (t/T) in purified C-peptide in urine at
baseline and in urine collected during the 13C leucine
OGTT was used as initial measurement. These numbers
were used for correlation analyses with routine OGTT
parameters. Leucine and precursor KIC enrichment are
expressed in mole per cent excess (MPE).
FSR of de novo insulin The FSR of C-peptide de novo
synthesis was calculated; FSR was expressed as percentage
(%) during OGTT and calculated with the following for-
mula [19, 22];
FSR %=hð Þ ¼ Ecollected  Ebasalð Þ=A 60min 100%
where Ecollected is the enrichment of leucine in purified
C-peptide from urine collected during the total duration of
the 13C leucine OGTT, Ebasal is the natural enrichment in
baseline urine and area (A) is the AUC in enrichment of
KIC from 90 to 210 min during OGTT and used as sub-
stitute for enrichment of precursor pool. The factor 100 is
used to convert FSR into %/h. Tracer-based synthesis
measurement is based on a series of events: firstly the
secretion time, which in this is case the period between
oral administration of 13C leucine and first appearance of
enriched C-peptide; secondly the period of de novo syn-
thesis of C-peptide. This period is used for calculation of
A; and thirdly the period of disappearance of stable iso-
tope 13C leucine and decrease in precursor enrichment.
Regarding these events, FSR calculation was based on a
fixed model: this model is based on earlier in vitro liter-
ature regarding biphasic responses, with a period of
secretion time for de novo synthesis within OGTT esti-
mated as 0–90 min post-glucose load [19]; period of de
novo synthesis was estimated as 90–210 min, and we
assumed this time period based on (1) previous literature
where in vitro isolated rodent islet cells exposed to high
glucose concentrations produced de novo insulin after
60 min [17, 18] and (2) taking into account both leucine
and glucose absorption in our gut; period of disappearance
of stable isotope is not taken into consideration in this
model.
Estimated absolute de novo C-peptide concentration in
both urine and plasma Total urinary C-peptide concen-
tration was multiplied with the overall fractional synthesis
(FS) during the 2 h of OGTT (t90–210 min) to obtain
absolute de novo C-peptide estimated in urine. Total
plasma C-peptide AUC was multiplied with FS during the
2 h of OGTT (t90–210 min) to obtain absolute de novo
C-peptide estimated in plasma.
Statistical analyses
Data are expressed as mean ± SD, or indicated otherwise.
Comparisons within persons were made with paired t test.
For correlation analyses, Spearman’s rho was used. Dif-
ferences were considered statistically significant when
P value was\0.05. All statistical tests were conducted with
the use of SPSS, version 15.0, for Windows (SPSS Inc.,
Chicago, IL, USA).
Results
Dosage, distribution, single-pool kinetics and final
conditions of the bolus dose method
First, the optimal conditions for stable isotope adminis-
tration during an OGTT were determined. We studied the
effect of 1.0 g 13C leucine administration on plasma
insulin concentrations among non-diabetics (n = 7,
M4F3, age 31.2 ± 16.1, BMI 23.2 ± 2.2), with paired
t test of insulin concentration in both groups before and
15 min after administration. Since no significant increase
in insulin or C-peptide concentration was observed, this
dosage was maintained (supplemental figure 2a). To test
whether 1.0 g 13C leucine and timing of administration
would result in enough precursor enrichment, we exam-
ined isotope enrichment in the extracellular fluid (leucine
MPE) and isotope enrichment in the intracellular fluid
(KIC MPE) in both plasma and saliva in non-diabetics
during OGTT (n = 6, M4F2, age 35.5 ± 17.4 BMI
23.9 ± 3.3). No significant difference in the amount of
average leucine MPE and KIC MPE/min between plasma
and saliva was observed after 13C leucine administration;
equilibrium with KIC MPE as valid surrogate marker was
assumed with high precursor enrichment (supplemental
figure 2b). With this final protocol, we combined the data
of total nine non-diabetic individuals (M4F5, age
31.9 ± 10.5, BMI 24.8 ± 3.0) into a final KIC MPE and
leucine MPE curve (Fig. 2). From this curve, the AUC
from t = 90 to t = 210 min was used to estimate A. As
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we observed a small variance in A, with a value of
0.109 ± SEM 0.016 (t120–210 min), we used this as a
fixed parameter in our final model. Single-pool kinetics of
both 13C leucine and 13C KIC in both plasma and saliva
are mentioned in supplemental table 1.
13C leucine enrichment and OGTT-based plasma/
urine parameters
We used our final model in 12 subjects with normal glu-
cose tolerance. Their general characteristics as well as their
enrichment measurements are described in Table 1,
detailed individual characteristics in supplemental table 2
and their OGTT curves in Fig. 3a. In general, 13C/12C
enrichment in C-peptide from basal urine (the naturally
occurring enrichment) did not differ much between sub-
jects. It was estimated that on average, de novo synthesis
represented *20 % of total C-peptide released during a
210-min OGTT. In correlation analyses with OGTT
parameters, 13C/12C leucine enrichment was negatively
correlated with early C-peptide release (Fig. 3b) and also
negatively correlated with excesses of glucose concentra-
tions (Fig. 3c). Finally, in order to demonstrate the trend of
enrichment post-glucose load, we collected multiple urine
voids during OGTT. Supplemental Fig. 3 illustrates that
13C/12C leucine enrichment had its maximum more
towards the late phase of the OGTT.
Discussion
Using 13C-leucine to label peptides during a 75-g OGTT in
healthy volunteers, we found that newly synthesized insu-
lin contributed a substantial portion (approximately 20 %)
to the secreted insulin during 210 min. The pattern of
isotope enrichment suggested that the newly synthesized
insulin contributed mainly to the second phase of insulin
secretion: the negative association of post-glucose load
Fig. 2 Final leucine and KIC enrichment curves (MPE, mean ± SD)
in healthy individuals (n = 9)
Table 1 Clinical characteristics





Age (years) 41.8 ± 2.3
Weight (kg) 88.2 ± 6.21
Height (m) 1.76 ± 0.03
BMI (kg/m2) 28.3 ± 1.7
Waist (cm) 101.8 ± 4.7
Hip (cm) 113.0 ± 2.85
W/H ratio 0.90 ± 0.02
RR systolic (mmHg) 121 ± 4
RR diastolic (mmHg) 76 ± 2
Basal C-peptide enrichment (t/T) 0.273 ± 0.0004
Collected C-peptide enrichment (t/T) 0.295 ± 0.002
FSR (%/h), total FS (%) during 210-min OGTT between brackets 9.9 ± 1.0 (19.8 ± 1.9)
Total urinary C-peptide (pmol/l*210 min) 8746 ± 1585
De novo urinary C-peptide (pmol/l*210 min) 1633 ± 305
Total plasma C-peptide AUC (pmol/l*210 min) 388,129 ± 35,252
De novo plasma C-peptide AUC (pmol/l*210 min) 74,367 ± 8727
Data are mean ± SEM
BMI Body mass index, W/H ratio waist/hip ratio, RR Riva-Rocci (blood pressure), FSR fractional synthesis
rate, FS fractional synthesis, OGTT oral glucose tolerance test, AUC area under curve
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C-peptide enrichment with early plasma C-peptide AUC
might imply that a low first phase of insulin secretion is
followed by a relatively high dependency on de novo
synthesis. This is the first in vivo study where stable iso-
tope labelling has been used to explore synthesis and
release of insulin in humans.
Early in vitro studies following radioactive labelled
insulin in pancreatic islets in response to high glucose
concentration demonstrated an increase in radioactive
insulin release after more than 1 h delay [17, 18]. More-
over, we had to consider both leucine and glucose
absorption in the gut. The observed enrichment during our
OGTT from 90 to 210 min suggests an increase in de novo
insulin production, while it has been assumed that roughly
only 15 % of stored insulin is being secreted by the pan-
creas when exposed to high glucose levels. The enrichment
of C-peptide in the presence of a large insulin storage
capacity of the pancreas supports the idea of a preferential
secretion of de novo insulin under high glucose load con-
ditions [25, 26]. In line, late phase in vivo insulin release in
our healthy volunteers was not fully explained by de novo
synthesis, as had been observed in vitro [27]. In Fig. 4, we
propose a schematic overview of insulin synthesis includ-
ing labelling with 13C-leucine, SGP, RRP and secretion of
granules.
C-peptide was preferred to insulin as a measure of
insulin biosynthesis and enrichment measurement. Both are
secreted in equimolar rate, but C-peptide is more
Fig. 3 OGTT curves (mean ± SEM) for a glucose, b insulin and c C-peptide. Spearman’s correlation of C-peptide enrichment (t/T) obtained
from urine collected during OGTT with OGTT parameters d C-peptide 0- to 60-min AUC and e glucose disposal 0- to 60-min AUC
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stable than insulin, is cleared predominantly by the kidneys
and has a higher availability due to its longer half time in
plasma as well as being secreted in higher amounts into
urine. In addition and in contrast to insulin, C-peptide does
not have a significant first-pass liver clearance or other
peripheral tissue degradation pathways, which vary largely
between individuals with different metabolic conditions
influencing insulin synthesis and turnover. Urine was
sampled during OGTT, as urine is easily available and
contains C-peptide in higher abundance than plasma, which
is an advantage for isolation of the small C-peptide. Uri-
nary C-peptide excretion reflects endogenous insulin
Fig. 4 Schematic overview of assessment of beta cell function with
stable isotope method during OGTT. Oral glucose load initiates beta
cell response in a biphasic secretion modus. Two pools of granules
(oval shaped) are responsible for insulin secretion (sphere shaped):
first-phase insulin release (dark spheres) is delivered by a RRP
located at the cell periphery (1) and second more sustainable phase
(light spheres) is delivered by a SGP located more distantly (2). The
SGP contains pre-existing insulin and insulin that is newly synthe-
sized during OGTT. This newly synthesized insulin (light spheres
with 13C labelling) can be measured with stable isotope techniques,
adding a novel beta cell function test to investigate T2D development
within classical OGTT
Acta Diabetol (2016) 53:935–944 941
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secretion [28] and provides a potential for a non-invasive
method to follow beta cell dynamics with stable isotopes.
13C leucine was used as a tracer, as insulin and C-pep-
tide contain six potential sites for enrichment. We assumed
that there would be negligible isotopic effects or recycling
of the stable isotope in the current setting [29–31]. We
cannot exclude a contribution of recycling of the tracer
present in basal proteins, but the isotope bolus method
during a restricted period reduces such effects to negligible
proportions. We also assumed that our measured general
distribution of precursor surrogate 13C KIC in plasma also
reflects enrichment in amino acid pools of pancreatic beta
cells [22, 32] and that the 13C leucine-enriched C-peptide
has the same properties during our purification procedures
as normal C-peptide [33]. Stimulation of protein synthesis
in peripheral tissue has been observed on administration of
amino acids [19, 23, 34]. Therefore, leucine as well as its
derivative KIC could have had effects on the beta cells,
albeit to a substantially lesser extent than glucose [35, 36],
but we did not find such a metabolic effect of administra-
tion of 13C leucine on insulin and C-peptide levels. We
believe this metabolic effect is minimized by using a bolus
dose technique instead of a flooding dose method or infu-
sion labelling techniques, resulting in a substantial lower
required amount of 13C leucine administration. The use of a
relatively low amount, together with the timing of admin-
istration of 13C leucine (45 min before glucose load), dif-
fers from previous studies in which a metabolic effect was
observed using substantially higher amounts of leucine
simultaneously with glucose [37]. Although a continuous
infusion labelling technique would result in a preferred
constant precursor enrichment, the bolus dose method is
less time-consuming with seemingly similar results [20],
and it has a proven capability to achieve equilibrium of
intra- and extracellular pancreatic amino acid pools
[19–21].
There are some technical considerations regarding the
use of tracer/tracee ratio in urinary C-peptide as marker for
de novo synthesis. C-peptide 13C enrichment could be
underestimated when there is still a demand for insulin and
presumably also for de novo insulin synthesis in the late
phase of the OGTT based on disappearance of label into
the extravascular pool. This would result in diminished
precursor enrichment. We have purified C-peptide from
human urine. This method is not only of benefit for further
C-peptide-oriented studies, but also provides an overview
of how to manage the purification of other low abundant
peptides from human bodily fluids. SPE-IAC demonstrated
highly purified C-peptide on 1D HPLC analysis, preventing
of loss of C-peptide by reduction in the number of steps
required for purification. Loss of C-peptide during work-up
procedure was also reduced by optimization of the surface
materials [38]. It remains the question whether or not this
procedure will suffice in individuals with T2D, with pos-
sible fewer quantities of urinary C-peptide, and excessive
urinary protein and peptide contamination due to diabetic
nephropathy.
Although our method used for enrichment measurements
was reproducible, urine C-peptide (ELISA measured) con-
centration was independent, and increased enrichment could
be observed when using 1 or 4 g of 13C leucine (supple-
mental figure 3) in the same individual, it is not a purely
quantitative method, as it is based on the ratio of labelled to
unlabelled C-peptide, rather than the absolute amount of
tracer. Considerations for qualitative or quantitative mea-
surements have been discussed previously [39]. Taken
together, the increase over time of enrichment after a leucine
bolus, the increase over time of the production of C-peptide
after a glucose load and the use of urine voidance instead of
blood make our results an overall approximation of de novo
synthesis of insulin during OGTT. With only two mea-
surements to determine the enrichment, the current model
simplifies the non-steady-state nature of insulin secretion
after an acute oral glucose stimulus for beta cell secretion.
Of course, the tracer 13C leucine enrichment could be
measured in frequently sampled plasma for more detail.
Further technical improvements to increase the recovery of
purified C-peptide (or insulin) from plasma and enhanced
mass spectrometry efficiency for measuring de novo syn-
thesis measurement are required if intravenous glucose
stimulus techniques are considered to test beta cell function.
Such an approach may make a clearer distinction between
the first-phase and the second-phase insulin response and
facilitates more detailed modelling [5].
The stable isotope labelling techniques used for this
study purpose provide a base for improved phenotyping of
individuals with metabolic syndrome and predisposition for
T2D, which could open the opportunity for the earlier
initiation of preventive beta cell focused strategies to
inhibit the progression to T2D. Moreover, our method
could also be applied for monitoring of beta cell capacity
during beta cell potentiating medication.
In conclusion, we have developed an in vivo stable iso-
tope tracer method to investigate beta cell dynamics in
humans that is able to distinguish between already avail-
able and de novo synthesized insulin. Future research is
required to test the value of the method to screen for
impaired insulin secretion as part of beta cell dysfunction.
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